Skip to main content

Table 1 Relationship between β1 integrin expression with clinicopathologic features and classical immunohistochemical markers in breast cancer, including VEGF

From: Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study

Clinicopathologic Features and Immunohistochemical Markers

β1 Integrin-

β1 Integrin+

P-value

  

n (151)

(%)

n (74)

(%)

 

Age (years)

<50

65

43.0

27

36.5

0.213a

>50

86

67.0

47

63.5

 

Menstrual Status

Pre-menopausal

54

35.8

24

32.4

0.367a

Post-menopausal

97

64.2

50

67.6

 

Size (mm)

<20

49

32.5

19

25.7

0.442b

20-50

55

36.4

33

44.6

 

>50

47

31.1

22

29.7

 

Tumoral Grade

I

57

37.7

25

33.8

0.845b

II

71

47.0

37

50.0

 

III

23

15.2

12

16.2

 

Lymph node Status

Negative

75

49.7

33

44.6

0.283a

Positive

76

50.3

41

55.4

 

Clinical Stage

I

22

14.6

10

13.5

0.677b

II

72

47.7

30

40.5

 

III

49

32.5

30

40.5

 

IV

8

5.3

4

5.4

 

Death

No

116

76.8

40

54.1

0.001 a

Yes

35

23.2

34

45.9

 

Metastasis

No

115

76.2

48

64.9

0.05 a

Yes

36

23.8

26

35.1

 

ER

Negative

48

31.8

21

28.4

0.359a

Positive

103

68.2

53

71.6

 

PR

Negative

64

42.4

33

44.6

0.431a

Positive

87

57.6

41

55.4

 

p53

Negative

114

75.5

51

68.9

0.187a

Positive

37

24.5

23

31.1

 

Ki-67

Negative

107

70.9

54

73.0

0.435a

Positive

44

29.1

20

27.0

 

HER2

Negative

126

83.4

52

70.3

0.019 a

Positive

25

16.6

22

29.7

 

VEGF

Negative

114

75.5

66

89.2

0.011 a

 

Positive

37

24.5

8

10.8

 
  1. aFisher’s exact test; bChi-square test.